David Scott, PhD, Scientific Director, Bioclinica, will explore the neurobiology of Parkinson’s Disease (PD) and DaTscan SPECT in the differential diagnosis of movement disorders, during a free live webinar on Tuesday, May 12, 2020 at 10:30am EDT (3:30pm BST/UK).
Attendees will learn about Volumetric MRI and Diffusion Tensor Imaging analytic techniques and how neuroimaging can enrich a clinical trial population, a media release from Xtalks notes.
Nigrostriatal dopaminergic denervation is a critical pathological event in Parkinson’s Disease (PD) and related disorders. Degeneration of presynaptic neurons leads to reduced density of dopamine transporters in the striatum, the progression of which leads to development of motor deficits and other clinical features.
DaTscan SPECT permits the in vivo assessment of striatal dopamine transporter (DAT) availability. Emerging evidence suggests that a pattern of reduced volume in the striatum and altered morphometry throughout the brain may inform the likelihood of progressive reduction in DaTscan binding.
In this webinar, Dr Scott will discuss how the integration of biomarkers across neuroimaging modalities can improve the characterization of PD disease state and help to predict whether a PD patient will reliably progress over the time frame of a clinical trial.
The webinar will present findings from the open source Parkinson’s Progression Markers Initiative database, which suggests that baseline volumetric MRI and diffusion tensor imaging (DTI) can meaningfully inform the longitudinal progression of DaTscan uptake in PD patients.
It will also explore the performance of different image-processing pipelines, analytic endpoints and anatomic localization to determine which combination is most sensitive in predicting disease progression, per the release.
For more information or to register, visit Neuroimaging in Parkinson’s Disease.
[Source(s): Xtalks, PRWeb]